Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

University of Sao Paulo

Status and phase

Completed

Phase 2

Conditions

Macular Degeneration

Macular Edema

Diabetic Retinopathy

Treatments

Drug: bevacizumab

Drug: brimonidine

Procedure: anterior chamber paracentesis

Drug: acetazolamide

Study type

Interventional

Funder types

Other

Identifiers

NCT00804921

IOP After Bevacizumab

Details and patient eligibility

About

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).

Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria